The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Bristol-Myers Squibb Co shares valued at $3,702 were sold by Hickey Benjamin on May 09 ’25. At $38.01 per share, Hickey Benjamin sold 97 shares. The insider’s holdings dropped to 0 shares worth approximately $0.0 following the completion of this transaction.
Also, Hirawat Samit purchased 4,250 shares, netting a total of over 202,215 in proceeds. Following the buying of shares at $47.58 each, the insider now holds 83,513 shares.
Before that, BOERNER CHRISTOPHER S. had added 2,000 shares to its account. In a trade valued at $110,096, the Chief Executive Officer bought Bristol-Myers Squibb Co shares for $55.05 each. Upon closing the transaction, the insider’s holdings increased to 2,000 shares, worth approximately $5.02 million.
As published in their initiating research note from Piper Sandler on April 22, 2025, Bristol-Myers Squibb Co [BMY] has been an Overweight. Analysts at Cantor Fitzgerald started covering the stock with ‘”a Neutral”‘ outlook in a report released in late April. As of December 16, 2024, Jefferies has increased its “Hold” rating to a “Buy” for BMY.
Analyzing BMY Stock Performance
During the last five days, there has been a surge of approximately 2.09%. Over the course of the year, Bristol-Myers Squibb Co shares have dropped approximately -15.22%. Shares of the company reached a 52-week high of $63.33 on 03/11/25 and a 52-week low of $44.00 on 05/14/25.
Support And Resistance Levels for Bristol-Myers Squibb Co (BMY)
According to the 24-hour chart, there is a support level at 47.65, which, if violated, would cause prices to drop to 47.35. In the upper region, resistance lies at 48.55. The next price resistance is at 49.15. RSI (Relative Strength Index) is 47.76 on the 14-day chart, showing neutral technical sentiment.
